Physician profile
Yuval Bibi
NPI 1740455682
$3,835.58
in general payments reported to CMS, 2019-2025
27 companies · $683 in 2025
The $683 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.46 · 2021: $256 · 2022: $821 · 2023: $1,058 · 2024: $1,003 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,729.08 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.52 | 2021-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $564.03 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $354.45 | 2021-2024 | Ilumya, Blu-U, Odomzo |
| Kerecis Limited | $318.17 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Novartis Pharmaceuticals Corporation | $268.00 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $238.10 | 2022-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $237.61 | 2022-2025 | |
| Janssen Biotech, INC. | $201.89 | 2022-2025 | Tremfya |
| Amgen INC. | $132.09 | 2022-2025 | Otezla, Otezla |
| Novo Nordisk INC | $73.79 | 2024 | |
| Organogenesis INC. | $73.50 | 2021-2023 | Puraply |
| Almirall LLC | $51.54 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $38.97 | 2022-2023 | Valchlor |
| Ucb, INC. | $37.98 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $37.70 | 2023 | Nuzyra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $36.88 | 2021-2024 | Erivedge |
| Lilly USA, LLC | $35.83 | 2022-2023 | Olumiant, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.40 | 2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $20.20 | 2023 | Sotyktu |
| Biofrontera INC. | $19.84 | 2022 | |
| Strata Skin Sciences, INC. | $18.82 | 2023 | Xtrac |
| Verrica Pharmaceuticals INC. | $18.06 | 2023 | Ycanth |
| Journey Medical Corporation | $17.98 | 2023 | |
| Merz North America, INC. | $16.19 | 2023 | Xeomin |
| Incyte Corporation | $15.02 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.46 | 2019 | |
| Organon LLC | $5.56 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuval Bibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.